Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy Are Associated With Increased Mortality and Poor Adherence to Therapy
- 1 November 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 40 (3) , 288-293
- https://doi.org/10.1097/01.qai.0000182847.38098.d1
Abstract
To examine the independent association of discordant virologic and immunologic responses to highly active antiretroviral therapy (HAART) with mortality. A population-based study of 1527 treatment-naive individuals initiating HAART used Cox proportional hazards modeling to determine the independent association of treatment response at 3 to 9 months with nonaccidental mortality. Logistic regression was used to examine associations with discordant responses. Viral load (VL)+/CD4− discordant responses were seen in 235 (15.4%) of subjects, and VL−/CD4+ responses were seen in 179 (11.7%) of subjects. In adjusted Cox regression models, discordant responses were found to be independently associated with an increased risk of mortality (VL+/CD4−: relative hazard [RH] = 1.87, 95% confidence interval [CI]: 1.15 to 3.04; VL−/CD4+: RH = 2.47, 95% CI: 1.54 to 3.95). VL+/CD4− discordance was found to be associated with increasing age, baseline HIV RNA load 100,000 copies/mL; the use of 3TC/ZDV, didanosine (ddI)/3TC, or ddI/stavudine; and poor adherence to therapy. Discordant responses are independently associated with an increased risk of mortality and are, in turn, associated with poor adherence to therapy.Keywords
This publication has 22 references indexed in Scilit:
- Can Immune Markers Predict Subsequent Discordance between Immunologic and Virologic Responses to Antiretroviral Therapy? Adult AIDS Clinical Trials GroupClinical Infectious Diseases, 2003
- Prolonged CD4+Cell/Virus Load Discordance during Treatment with Protease Inhibitor–Based Highly Active Antiretroviral Therapy: Immune Response and Viral ControlThe Journal of Infectious Diseases, 2003
- Prognostic Factors of Combined Viral Load and CD4+ Cell Count Responses Under Triple Antiretroviral Therapy, Aquitaine Cohort, 1996–1998JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Long‐Term Clinical Outcome of Human Immunodeficiency Virus–Infected Patients with Discordant Immunologic and Virologic Responses to a Protease Inhibitor–Containing RegimenThe Journal of Infectious Diseases, 2001
- Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral TherapyAnnals of Internal Medicine, 2000
- Residual Low-Level Viral Replication Could Explain Discrepancies between Viral Load and CD4+ Cell Response in Human Immunodeficiency Virus—Infected Patients Receiving Antiretroviral TherapyClinical Infectious Diseases, 2000
- Discrepant responses to triple combination antiretroviral therapy in advanced HIV diseaseAIDS, 1998
- A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected PatientsJAMA, 1998
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997